Drugmakers Sanofi, Eli Lilly, Novo Nordisk and AstraZeneca must face a lawsuit from two health centers accusing them of ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Digitization has allowed Sanofi to optimize manufacturing and automate document preparation. And now, the firm predicts that ...

Fintel reports that on August 8, 2025, JP Morgan upgraded their outlook for Sanofi - Depositary Receipt () (NasdaqGS:SNY) ...

Drugmaker Sanofi said on Thursday it believes the impact from U.S. tariffs to be manageable as it raised its sales growth ...

The study began on April 11, 2021, and was last updated on August 4, 2025. However, it has been terminated, which could impact the timeline for any potential market release of SAR444881.

For now, Sanofi’s U.S. inventory is insulating the company from a potential 15% tariff on drugs shipped from the EU.

The pharmaceutical company’s top line grew faster than analysts expected for the second quarter due to drug launches and ...

French pharmaceutical giant Sanofi reported a sharp increase in second-quarter profit on Thursday, driven by higher net sales ...

Sanofi Consumer Healthcare India reports ₹220 crore revenue, ₹60 crore profit, driven by exports, product launches, and ...